Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 7
1996 3
1997 6
1998 7
1999 5
2000 5
2001 4
2002 18
2003 10
2004 9
2005 10
2006 8
2007 13
2008 13
2009 15
2010 7
2011 10
2012 19
2013 8
2014 10
2015 9
2016 12
2017 10
2018 4
2019 6
2020 6
2021 7
2022 4
2023 11
2024 10
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Did you mean valacyclovir (237 results)?
Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: a randomised, double-blind, placebo-controlled trial.
Shahar-Nissan K, Pardo J, Peled O, Krause I, Bilavsky E, Wiznitzer A, Hadar E, Amir J. Shahar-Nissan K, et al. Lancet. 2020 Sep 12;396(10253):779-785. doi: 10.1016/S0140-6736(20)31868-7. Lancet. 2020. PMID: 32919517 Clinical Trial.
FINDINGS: Between Nov 15, 2015, and Oct 8, 2018, we enrolled and randomly assigned 100 patients to receive valaciclovir or placebo. Ten patients were excluded, five from each study group; therefore, the final analysis included 45 patients (all singletons) in the valacic …
FINDINGS: Between Nov 15, 2015, and Oct 8, 2018, we enrolled and randomly assigned 100 patients to receive valaciclovir or placebo. T …
Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial.
Linden DA, Guo-Parke H, McKelvey MC, Einarsson GG, Lee AJ, Fairley DJ, Brown V, Lundy G, Campbell C, Logan D, McFarland M, Singh D, McAuley DF, Taggart CC, Kidney JC. Linden DA, et al. Chest. 2023 Sep;164(3):625-636. doi: 10.1016/j.chest.2023.03.040. Epub 2023 Apr 1. Chest. 2023. PMID: 37011709 Free PMC article. Clinical Trial.

A greater number of participants in the valaciclovir group achieved EBV suppression (n = 36 [87.8%] vs n = 17 [42.5%]; P < .001). ...INTERPRETATION: Valaciclovir is safe and effective for EBV suppression in COPD and may attenuate the sputum inflammatory cell infi

…

A greater number of participants in the valaciclovir group achieved EBV suppression (n = 36 [87.8%] vs n = 17 [42.5%]; P < .001).

…
Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus: The Zoster Eye Disease Randomized Clinical Trial.
Cohen EJ, Troxel AB, Liu M, Hochman JS, Baratz KH, Mian SI, Choulakian MY, Warner DB, Lu Y, Twi-Yeboah A, Lee TF, Kim J, Lopez-Jimenez C, Laury SC, Jeng BH; ZEDS Trial Research Group. Cohen EJ, et al. JAMA Ophthalmol. 2025 Apr 1;143(4):269-276. doi: 10.1001/jamaophthalmol.2024.6114. JAMA Ophthalmol. 2025. PMID: 40048183 Free PMC article. Clinical Trial.
At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. ...These results support consideration …
At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at …
Antiviral treatment for acute retinal necrosis: A systematic review and meta-analysis.
Putera I, Ridwan AS, Dewi M, Cifuentes-González C, Rojas-Carabali W, Sitompul R, Edwar L, Susiyanti M, Aziza Y, Pavesio C, Chee SP, Mahendradas P, Biswas J, Kempen JH, Gupta V, de-la-Torre A, La Distia Nora R, Agrawal R. Putera I, et al. Surv Ophthalmol. 2024 Jan-Feb;69(1):67-84. doi: 10.1016/j.survophthal.2023.09.004. Epub 2023 Sep 27. Surv Ophthalmol. 2024. PMID: 37774799 Free article.
Effectiveness and safety of prenatal valacyclovir for congenital cytomegalovirus infection: systematic review and meta-analysis.
D'Antonio F, Marinceu D, Prasad S, Khalil A. D'Antonio F, et al. Ultrasound Obstet Gynecol. 2023 Apr;61(4):436-444. doi: 10.1002/uog.26136. Ultrasound Obstet Gynecol. 2023. PMID: 36484439 Free article.
Head-to-head meta-analyses were used to compare the risk of each of the explored outcomes according to whether pregnancies with maternal CMV infection were treated with prenatal valacyclovir therapy. RESULTS: Eight studies (620 women) were included. Pregnancies treated wit …
Head-to-head meta-analyses were used to compare the risk of each of the explored outcomes according to whether pregnancies with maternal CMV …
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.
Tan DHS, Raboud JM, Szadkowski L, Grinsztejn B, Madruga JV, Figueroa MI, Cahn P, Barton SE, Clarke A, Fox J, Zubyk W, Walmsley SL; VALIDATE Study Group. Tan DHS, et al. J Antimicrob Chemother. 2019 Feb 1;74(2):480-488. doi: 10.1093/jac/dky433. J Antimicrob Chemother. 2019. PMID: 30376108 Free PMC article. Clinical Trial.
CONCLUSIONS: Unlike prior trials using aciclovir, we found that valaciclovir did not slow CD4 count decline in cART-untreated adults, although power was limited due to premature study discontinuation. Valaciclovir modestly lowered HIV VL....
CONCLUSIONS: Unlike prior trials using aciclovir, we found that valaciclovir did not slow CD4 count decline in cART-untreated adults, …
Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M; Valacyclovir HSV Transmission Study Group. Corey L, et al. N Engl J Med. 2004 Jan 1;350(1):11-20. doi: 10.1056/NEJMoa035144. N Engl J Med. 2004. PMID: 14702423 Free article. Clinical Trial.
The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months. The susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes. ...CONCLUSIONS: Once-daily suppressive …
The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight mon …
The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis.
Chatzakis C, Shahar-Nissan K, Faure-Bardon V, Picone O, Hadar E, Amir J, Egloff C, Vivanti A, Sotiriadis A, Leruez-Ville M, Ville Y. Chatzakis C, et al. Am J Obstet Gynecol. 2024 Feb;230(2):109-117.e2. doi: 10.1016/j.ajog.2023.07.022. Epub 2023 Jul 18. Am J Obstet Gynecol. 2024. PMID: 37473793
This individual patient data meta-analysis aimed to assess the effectiveness and safety of valacyclovir treatment in the secondary prevention of congenital cytomegalovirus infection. ...Valacyclovir reduced the vertical transmission rate of cytomegalovirus (adjusted …
This individual patient data meta-analysis aimed to assess the effectiveness and safety of valacyclovir treatment in the secondary pr …
Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials.
Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ; International Valaciclovir HSV Study Group. Conant MA, et al. Int J STD AIDS. 2002 Jan;13(1):12-21. doi: 10.1258/0956462021924550. Int J STD AIDS. 2002. PMID: 11802924 Clinical Trial.
Valaciclovir was as effective as aciclovir for suppression and episodic treatment of herpes. ...Valaciclovir 500 mg twice daily was superior to 1000 mg once daily, P=0.001. Valaciclovir 1000 mg twice daily was comparable to aciclovir on herpes episode duratio …
Valaciclovir was as effective as aciclovir for suppression and episodic treatment of herpes. ...Valaciclovir 500 mg twice dail …
Different dosages of valaciclovir for the treatment of herpes zoster in adults: A randomized clinical study.
Yao H, Zhu C, Liu L, Hu H. Yao H, et al. J Clin Pharm Ther. 2021 Jun;46(3):717-723. doi: 10.1111/jcpt.13336. Epub 2020 Dec 25. J Clin Pharm Ther. 2021. PMID: 33368338 Clinical Trial.
Patients in the two age groups were then prescribed different doses of valaciclovir. The high-dose group was administered 900 mg of valaciclovir, three times daily for 10 days, whereas the low-dose group was administered 300 mg of valaciclovir, two times dail …
Patients in the two age groups were then prescribed different doses of valaciclovir. The high-dose group was administered 900 mg of …
253 results